S100A9 and neoplasm: Indeed, inhibition of S100A9 using quinoline-3-carboxamide derivatives such as tasquinimod has shown anti-tumor effects in several pre-clinical models, through modulation of the tumor microenvironment; tasquinimod inhibited myeloid-derived suppressor cell recruitment and infiltration, leading to enhanced tumor immunity and decreased angiogenesis.43 Our study further indicates that targeting S100A9 may have additional direct effects on cancer cells, by suppressing their invasive and migratory capabilities.